Patient characteristics
| Characteristic . | Value . |
|---|---|
| Patients, n | 46 |
| Age, y | |
| Median | 53 |
| Range | 1-68 |
| Sex | |
| Female | 22 |
| Male | 24 |
| Prior regimens | |
| Median | 3 |
| Range | 1-5 |
| Previous allogeneic transplant, n (%) | 8 (17) |
| Unrelated donor, n (%) | 26 (56) |
| HLA mismatched donor, n (%) | 6 (14) |
| Comorbidity index* | |
| Median | 3 |
| Range | 0-9 |
| Diagnosis to HSCT, mo | |
| Median | 10 |
| Range | 2-123 |
| Disease, n (%) | |
| AML | 31 (68) |
| CML | 2 (4) |
| ALL | 4 (9) |
| CLL | 4 (9) |
| NHL | 3 (6) |
| MDS | 1 (2) |
| MM | 1 (2) |
| Clofarabine dose, n (%) | |
| 20 mg/m2 | 6 (13) |
| 30 mg/m2 | 21 (46) |
| 40 mg/m2 | 19 (41) |
| Characteristic . | Value . |
|---|---|
| Patients, n | 46 |
| Age, y | |
| Median | 53 |
| Range | 1-68 |
| Sex | |
| Female | 22 |
| Male | 24 |
| Prior regimens | |
| Median | 3 |
| Range | 1-5 |
| Previous allogeneic transplant, n (%) | 8 (17) |
| Unrelated donor, n (%) | 26 (56) |
| HLA mismatched donor, n (%) | 6 (14) |
| Comorbidity index* | |
| Median | 3 |
| Range | 0-9 |
| Diagnosis to HSCT, mo | |
| Median | 10 |
| Range | 2-123 |
| Disease, n (%) | |
| AML | 31 (68) |
| CML | 2 (4) |
| ALL | 4 (9) |
| CLL | 4 (9) |
| NHL | 3 (6) |
| MDS | 1 (2) |
| MM | 1 (2) |
| Clofarabine dose, n (%) | |
| 20 mg/m2 | 6 (13) |
| 30 mg/m2 | 21 (46) |
| 40 mg/m2 | 19 (41) |
CML indicates chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; and NHL, non-Hodgkin lymphoma.
Comorbidity index as reported by Sorror et al.19